FindMyKOL

Joseph Buscema, MD

Basic profile

Tucson Medical Center

ORCIDOn fileNPIOn fileSign in to see identifiers
✓ Itemized record
RegionTucson, AZ · WestSpecialtyGynecologic OncologyFocusOncology
Active KOLEmergingFindMyKOL type: RegionalLatest publicationSee ScholarshipOnline presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Joseph Buscema is an Oncology physician affiliated with Tucson Medical Center. OpenAlex indexes 99 publications with 5,682 citations (h-index 26).

Overview

Scholarship

indexed output and impact (OpenAlex)
99publications

Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.

5,682citations

Citations across these publications.

26h-index

H-index from these publications.

Clinical & industry

trials, payments and federal funding
29companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓

Industry payments

29 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

  • Genmab
    Program year20254 paymentsResearch
    $196,293
  • Daiichi Sankyo
    Program year2025245 paymentsResearch
    $174,446
  • GSK
    Program year202517 paymentsResearch
    $53,763
All 90 payment records: search, sort and filter.Explore →

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Metabolism & gastrointestinal

    40.1%
    Substance P/Neurokinin-1 Receptor Antagonist32.8%
    Aprepitant100%
    Part B, office-administered≥25 patients
    Serotonin-3 Receptor Antagonist7.1%
    Palonosetron hcl59%Granisetron hydrochloride40%Ondansetron Odt2%
    Part D + Part B≥40 patients

    + 3 more classes in this area

  • Cancer & immunology

    25.9%
    Microtubule Inhibitor24.8%
    Paclitaxel100%
    Part B, office-administered≥16 patients
    Platinum-based Drug0.8%
    Carboplatin100%
    Part B, office-administered≥16 patients

    + 3 more classes in this area

  • Blood & clotting

    19.6%
    Erythropoiesis-stimulating Agent16.2%
    Darbepoetin alfa100%
    Part B, office-administered≥11 patients
    Iron, parenteral preparations3.3%
    Ferric derisomaltose100%
    Part B, office-administered≥11 patients

    + 1 more class in this area

Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”